Immune Cells in Cancer Therapy and Drug Delivery

Eyileten, Ceren; Majchrzak, Kinga; Pilch, Zofia; Tonecka, Katarzyna; Mucha, Joanna; Taciak, Bartłomiej; Ulewicz, Katarzyna; Witt, Katarzyna; Boffi, Alberto; Król, Magdalena; Rygiel, Tomasz P.

doi:10.1155/2016/5230219

Cited by 26 publications

(15 citation statements)

References 123 publications

(128 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NK is a heterogeneous cell population (cytotoxic, immunoregulatory, and memory cells) which have been described as critical effectors in tumor immunology with attributes of both innate and adaptive immunity ( 52 , 53 ). Moreover, recent clinical data provide evidence of NK cell activity against hematologic malignancies, which could be translated into feature therapeutic strategies ( 54 , 55 ).…”

Section: Discussionmentioning

confidence: 99%

Salmonella Immunotherapy Improves the Outcome of CHOP Chemotherapy in Non-Hodgkin Lymphoma-Bearing Mice

et al. 2018

View full text Add to dashboard Cite

We have previously shown that Salmonella immunotherapy is effective to treat B-cell non-Hodgkin lymphoma (B-NHL) in mice. However, this model involves animals with high tumor burden, whereas in the clinics B-NHL patients are usually treated with chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone) as first-line therapy prior to immunotherapy. Recently, we have described a NHL-B preclinical model using CHOP chemotherapy to achieve MRD in immunocompetent animals that closely resemble patients’ conditions. In this work, we assessed the efficacy of Salmonella immunotherapy in B-NHL-bearing mice undergoing chemotherapy. Salmonella administration significantly delayed tumor growth and prolonged survival of chemotherapy-treated NHL-bearing animals. Mice receiving the CHOP–Salmonella combined therapy showed increased numbers of tumor-infiltrating leukocytes and a different profile of cytokines and chemokines expressed in the tumor microenvironment. Further, Salmonella immunotherapy in CHOP-treated animals also enhanced NK cells cytotoxic activity as well as induced systemic lymphoma-specific humoral and cellular responses. Chemotherapy treatment profoundly impacted on the general health status of recipient animals, but those receiving Salmonella showed significantly better overall body condition. Altogether, the results clearly demonstrated that Salmonella immunotherapy could be safely used in individuals under CHOP treatment, resulting in a better prognosis. These results give strong support to consider Salmonella as a neoadjuvant therapy in a clinical setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Salmonella Immunotherapy Improves the Outcome of CHOP Chemotherapy in Non-Hodgkin Lymphoma-Bearing Mice

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Cancer immunity is mainly conferred by the natural killer cells and natural killer T cells of the innate immune system, by helper and cytotoxic T cells, and by humoral immunity via antibody-producing B cells [ 13 ]. The relative contributions of innate and acquired immunity have been well studied and continue to be debated [ 10 , 14 – 16 ].…”

Section: Discussionmentioning

confidence: 99%

B-cell populations are expanded in breast cancer patients compared with healthy controls

et al. 2017

View full text Add to dashboard Cite

BackgroundHistorically, humoral immunity was considered unimportant in anti-tumor immunity, and the differentiation and anti-tumor activity of B cells in breast cancer are poorly understood. However, it was recently discovered that B cells participate in tumor immunity through both antibody production and immunosuppressive mechanisms. We analyzed the expression of B-cell differentiation markers in detail using fluorescence-activated cell sorting to investigate the relationship between B-cell subsets and breast cancer etiology.MethodsBlood samples were taken from breast cancer patients and healthy donors, and peripheral blood mononuclear cells were collected. B cells at various stages of differentiation were identified by the expression of combinations of the cell surface markers CD5, CD19, CD21, CD24, CD27, CD38, CD45, and IgD. Statistical analysis of the proportions of each B-cell subtype in the different patient groups was then performed.ResultsTwenty-seven breast cancer patients and 12 controls were considered. The proportion of total B cells was significantly higher in cancer patients than in controls (11.51 ± 2.059 vs 8.905 ± 0.379%, respectively; p = 0.001). Breast cancer patients were then classified as High-B or Low-B for further analysis. A significantly higher proportion of memory B cells was found in the High-B group than in the Low-B or control groups (p = 0.003 and p = 0.043, respectively).ConclusionsBreast cancer patients generally have a higher proportion of B cells than healthy controls, but this is highly variable. Analysis of the major B-cell surface markers indicates that memory B cells in particular are significantly expanded, or more robust, in breast cancer patients.Electronic supplementary materialThe online version of this article (10.1007/s12282-017-0824-6) contains supplementary material, which is available to authorized users.

show abstract

“…6a) or into the interior (Fig. 6b, top) of microrobots 25,44,156 , analogous to principles established for nanocarriers 157 . Finally, cells can be exploited as drug reservoirs in cellular and hybrid microrobots (Fig.…”

Section: Microrobot-induced Killing Mechanismsmentioning

confidence: 63%

Engineering microrobots for targeted cancer therapies from a medical perspective

et al. 2020

View full text Add to dashboard Cite

Systemic chemotherapy remains the backbone of many cancer treatments. Due to its untargeted nature and the severe side effects it can cause, numerous nanomedicine approaches have been developed to overcome these issues. However, targeted delivery of therapeutics remains challenging. Engineering microrobots is increasingly receiving attention in this regard. Their functionalities, particularly their motility, allow microrobots to penetrate tissues and reach cancers more efficiently. Here, we highlight how different microrobots, ranging from tailor-made motile bacteria and tiny bubble-propelled microengines to hybrid spermbots, can be engineered to integrate sophisticated features optimised for precision-targeting of a wide range of cancers. Towards this, we highlight the importance of integrating clinicians, the public and cancer patients early on in the development of these novel technologies.

show abstract

Immune Cells in Cancer Therapy and Drug Delivery

Cited by 26 publications

References 123 publications

Salmonella Immunotherapy Improves the Outcome of CHOP Chemotherapy in Non-Hodgkin Lymphoma-Bearing Mice

Salmonella Immunotherapy Improves the Outcome of CHOP Chemotherapy in Non-Hodgkin Lymphoma-Bearing Mice

B-cell populations are expanded in breast cancer patients compared with healthy controls

Engineering microrobots for targeted cancer therapies from a medical perspective

Contact Info

Product

Resources

About